JG
CCXI

Joel Greenblatt’s ChemoCentryx, Inc. CCXI Stock Holding History

Joel Greenblatt’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,636
Closed -$539K – 1252
2019
Q4 		$539K Buy
+13,636
New +$239K 0.01% 793
2018
Q3 		– Sell
-11,717
Closed -$154K – 1048
2018
Q2 		$154K Buy
+11,717
New +$140K ﹤0.01% 850

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Joel Greenblatt's CCXI Position: Q1 2020 in Review

Joel Greenblatt sold out of ChemoCentryx, Inc. (CCXI) in Q1 2020, closing a stake of 13,636 shares — an estimated $539K sold.

Joel Greenblatt first reported a position in CCXI in Q2 2018 and held it in 2 quarters. The position peaked at $539K in Q4 2019. 162 funds tracked by Wall St. Rank hold CCXI as of Q1 2020.

  • Joel Greenblatt reported no remaining ChemoCentryx, Inc. position as of Q1 2020 after selling out during the quarter.
  • Joel Greenblatt sold 13,636 ChemoCentryx, Inc. shares in Q1 2020, an estimated $539K.
  • Joel Greenblatt first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 2 quarters.
  • Joel Greenblatt's ChemoCentryx, Inc. position peaked at $539K in Q4 2019.
  • 162 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2020.

Based on Gotham Asset Management's 13F filing for Q1 2020, filed 15 May 2020.